Keywords: کارپپتین; erythropoietin; darbepoetin; cognitive development; very low birth weight; neurodevelopmental outcome; Darbe; Darbepoetin alfa; Epo; Erythropoietin; ESA; Erythropoiesis-stimulating agents; BASC-2; Behavioral Assessment System of Children - Second Editio
مقالات ISI کارپپتین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: کارپپتین; Anemia; Transfusions; Neuroprotection; Neurodevelopment; Darbepoetin; Erythropoiesis-stimulating agents;
Keywords: کارپپتین; chemotherapy-induced anemia; darbepoetin; epoetin; erythropoiesis-stimulating agent;
Novel, selective EPO receptor ligands lacking erythropoietic activity reduce infarct size in acute myocardial infarction in rats
Keywords: کارپپتین; Na-pentobarbital (PubChem CID:4737); Erythropoietin, Darbepoetin, B-type natriuretic peptide (PubChem CID:16132422); Cyclosporine A (PubChem CID:16404350); Trypan blue (PubChem CID:6364561); Evans blue dye (PubChem CID:5359386); 2,3,5-Triphenyltetrazolium
A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial
Keywords: کارپپتین; Anemia; chronic kidney disease (CKD); darbepoetin; drug sensitivity; epoetin; erythropoiesis-stimulating agent (ESA); ESA hyporesponsiveness; ESA resistance index (ERI); erythropoietin; pentoxifylline; hemoglobin; dialysis; randomized controlled trial;
Erythropoiesis-Stimulating Agent Use Among Non-Dialysis-Dependent CKD Patients Before and After the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) Using a Large US Health Plan Database
Keywords: کارپپتین; Erythropoietin-stimulating agent (ESA); epoetin (EPO); darbepoetin; predialysis chronic kidney disease (CKD); TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy); hemoglobin; anemia; prescribing patterns; Choose Wisely campaign; Thomson Reu
A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A “Half-and-Half” Combination Therapy
Keywords: کارپپتین; combination therapy; darbepoetin; epoetin; hemodialysis patients
Patients with anaemia can shift from kidney to liver production of erythropoietin as shown by glycoform analysis
Keywords: کارپپتین; EPO; Epoetin; Darbepoetin; Haemodialysis; Lectin chromatography; WGA
Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis
Keywords: کارپپتین; Erythropoietin; erythropoiesis-stimulating agent (ESA); epoetin; darbepoetin; anemia; chronic kidney disease (CKD); dose; mortality; cardiovascular morbidity; metaregression;
Qualitative and quantitative assessment of marketed erythropoiesis-stimulating agents by capillary electrophoresis
Keywords: کارپپتین; Erythropoietin; Darbepoetin; Formulation; Capillary electrophoresis; Erythropoiesis stimulating agent
Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes
Keywords: کارپپتین; Recombinant erythropoietin; Darbepoetin; G-CSF; Myelodysplastic syndromes; Transfusion; Anemia; Survival; Prognosis
Correcting Anemia in Heart Failure: The Efficacy and Safety of Erythropoiesis-Stimulating Agents
Keywords: کارپپتین; Erythropoiesis-stimulating agents; hemantics; erythropoietin; darbepoetin; anemia; chronic heart failure
Proteomic profiling during atherosclerosis progression using SELDI-TOF-MS: Effect of darbepoetin treatment
Keywords: کارپپتین; Atherosclerosis; Apolipoprotein E-deficient mice; Proteomics; Darbepoetin; SELDI-TOF-MS
Carbamylated darbepoetin derivative prevents endothelial progenitor cell damage with no effect on angiogenesis
Keywords: کارپپتین; EPCs; endothelial progenitor cells; EPO; erythropoietin; CKD; chronic kidney disease; rHuEPO; recombinant human erythropoietin; darbe; darbepoetin; C-darbe; carbamylated darbepoetin; TNBSA; trinitrobenzenesulfonic acid; PCNA; proliferating cell nuclear an
Diagnosis and Treatment of Anemia of Chronic Kidney Disease in the Primary Care Setting: A Primer for Nurse Practitioners
Keywords: کارپپتین; Anemia; chronic kidney disease; darbepoetin; epoetin; ESAs (erythropoiesis-stimulating agents); predialysis
Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study
Keywords: کارپپتین; erythropoiesis-stimulating agents; darbepoetin; hemodialysis; hemoglobin variability;
Incidence of symptomatic deep venous thrombosis with epoetin alfa or darbepoetin alfa treatment of anemia in patients with ovarian or primary peritoneal cancer
Keywords: کارپپتین; Ovarian cancer; Peritoneal cancer; Anemia; Epoetin; Darbepoetin; Chemotherapy
Quality of life in patients with myelodysplastic syndromes
Keywords: کارپپتین; Myelodysplastic syndromes; Quality of life; Erythropoietin; Darbepoetin; Haemochromatosis; Deferasinox; Lenalidomide; Decitabine;
Erythropoiesis-stimulating agents: Past and future
Keywords: کارپپتین; darbepoetin; erythropoietin; hypoxia; chronic kidney disease;
Phase III clinical trials with darbepoetin: implications for clinicians
Keywords: کارپپتین; darbepoetin; anemia; chemotherapy;
Evidence-based medicine: can it be applied to stimulation of erythropoiesis for patients with malignancy?
Keywords: کارپپتین; evidence-based decision-making; erythropoiesis; health care; erythropoietin; darbepoetin;